405 related articles for article (PubMed ID: 29162699)
21. DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K
PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623
[TBL] [Abstract][Full Text] [Related]
22. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells.
Oikawa T; Wauthier E; Dinh TA; Selitsky SR; Reyna-Neyra A; Carpino G; Levine R; Cardinale V; Klimstra D; Gaudio E; Alvaro D; Carrasco N; Sethupathy P; Reid LM
Nat Commun; 2015 Oct; 6():8070. PubMed ID: 26437858
[TBL] [Abstract][Full Text] [Related]
23. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
[TBL] [Abstract][Full Text] [Related]
24. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
[TBL] [Abstract][Full Text] [Related]
25. Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma.
Tomasini MD; Wang Y; Karamafrooz A; Li G; Beuming T; Gao J; Taylor SS; Veglia G; Simon SM
Sci Rep; 2018 Jan; 8(1):720. PubMed ID: 29335433
[TBL] [Abstract][Full Text] [Related]
26. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
[TBL] [Abstract][Full Text] [Related]
27. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
[TBL] [Abstract][Full Text] [Related]
28. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G; Simon SM
Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
[TBL] [Abstract][Full Text] [Related]
29. Advances in fibrolamellar hepatocellular carcinoma: a review.
Lim II; Farber BA; LaQuaglia MP
Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
[TBL] [Abstract][Full Text] [Related]
30. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
[TBL] [Abstract][Full Text] [Related]
31. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
32. Genomic analysis of fibrolamellar hepatocellular carcinoma.
Xu L; Hazard FK; Zmoos AF; Jahchan N; Chaib H; Garfin PM; Rangaswami A; Snyder MP; Sage J
Hum Mol Genet; 2015 Jan; 24(1):50-63. PubMed ID: 25122662
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins.
Averill AM; Rehman HT; Charles JW; Dinh TA; Danyal K; Verschraegen CF; Stein GS; Dostmann WR; Ramsey JE
J Cell Biochem; 2019 Aug; 120(8):13783-13791. PubMed ID: 30938854
[TBL] [Abstract][Full Text] [Related]
34. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
35. FGFR1 and FGFR2 in fibrolamellar carcinoma.
Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
[TBL] [Abstract][Full Text] [Related]
36. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
Graham RP; Torbenson MS
Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
[TBL] [Abstract][Full Text] [Related]
37. Structural analyses of the PKA RIIβ holoenzyme containing the oncogenic DnaJB1-PKAc fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma.
Lu TW; Aoto PC; Weng JH; Nielsen C; Cash JN; Hall J; Zhang P; Simon SM; Cianfrocco MA; Taylor SS
PLoS Biol; 2020 Dec; 18(12):e3001018. PubMed ID: 33370777
[TBL] [Abstract][Full Text] [Related]
38. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.
Simon EP; Freije CA; Farber BA; Lalazar G; Darcy DG; Honeyman JN; Chiaroni-Clarke R; Dill BD; Molina H; Bhanot UK; La Quaglia MP; Rosenberg BR; Simon SM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):E5916-25. PubMed ID: 26489647
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
40. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]